Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Tom70 serves as a molecular switch to determine pathological cardiac hypertrophy.

Authors: Li, Jun  Qi, Man  Li, Changming  Shi, Dan  Zhang, Dasheng  Xie, Duanyang  Yuan, Tianyou  Feng, Jing  Liu, Yi  Liang, Dandan  Xu, Xinran  Chen, Jinjin  Xu, Liang  Zhang, Hong  Ye, Jiangchuan  Lv, Fei  Huang, Jian  Peng, Luying  Chen, Yi-Han 
Citation: Li J, etal., Cell Res. 2014 Aug;24(8):977-93. doi: 10.1038/cr.2014.94. Epub 2014 Jul 15.
Pubmed: (View Article at PubMed) PMID:25022898
DOI: Full-text: DOI:10.1038/cr.2014.94

Pathological cardiac hypertrophy is an inevitable forerunner of heart failure. Regardless of the etiology of cardiac hypertrophy, cardiomyocyte mitochondrial alterations are always observed in this context. The translocases of mitochondrial outer membrane (Tom) complex governs the import of mitochondrial precursor proteins to maintain mitochondrial function under pathophysiological conditions; however, its role in the development of pathological cardiac hypertrophy remains unclear. Here, we showed that Tom70 was downregulated in pathological hypertrophic hearts from humans and experimental animals. The reduction in Tom70 expression produced distinct pathological cardiomyocyte hypertrophy both in vivo and in vitro. The defective mitochondrial import of Tom70-targeted optic atrophy-1 triggered intracellular oxidative stress, which led to a pathological cellular response. Importantly, increased Tom70 levels provided cardiomyocytes with full resistance to diverse pro-hypertrophic insults. Together, these results reveal that Tom70 acts as a molecular switch that orchestrates hypertrophic stresses and mitochondrial responses to determine pathological cardiac hypertrophy.

Annotation

Disease Annotations
Gene Ontology Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 13464131
Created: 2017-12-22
Species: All species
Last Modified: 2017-12-22
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.